Branger C, Chatrenet B, Gauvrit A, Aviat F, Aubert A, Bach J M, André-Fontaine G
Leptospira Medical and Molecular Bacteriology Unit, Ecole Nationale Vétérinaire de Nantes, France.
Infect Immun. 2005 Jul;73(7):4062-9. doi: 10.1128/IAI.73.7.4062-4069.2005.
The use of DNA constructs encoding leptospiral proteins is a promising new approach for vaccination against leptospirosis. In previous work we determined that immunization with hemolysis-associated protein 1 (Hap1) (LipL32) expressed by adenovirus induced significant protection against a virulent Leptospira challenge in gerbils. To avoid the use of the adenovirus vector, we checked for clinical protection against lethal challenge by DNA vaccination. A DNA vaccine expressing Hap1 was designed to enhance the direct gene transfer of this protein into gerbils. A challenge was performed 3 weeks after the last immunization with a virulent strain of serovar canicola. Our results show that the cross-protective effect with pathogenic strains of Leptospira, shared by Hap1, could be mediated by the DNA plasmid vector. This finding should facilitate the design and development of a new generation of vaccines against bacteria, particularly Leptospira interrogans sensu lato.
使用编码钩端螺旋体蛋白的DNA构建体是一种很有前景的新型钩端螺旋体病疫苗接种方法。在之前的工作中,我们确定用腺病毒表达的溶血相关蛋白1(Hap1)(LipL32)免疫能在沙鼠中诱导出对强毒钩端螺旋体攻击的显著保护作用。为避免使用腺病毒载体,我们通过DNA疫苗接种来检测对致死性攻击的临床保护作用。设计了一种表达Hap1的DNA疫苗,以增强该蛋白向沙鼠的直接基因转移。在用犬型血清型强毒株进行最后一次免疫3周后进行攻击。我们的结果表明,Hap1所具有的与钩端螺旋体致病菌株的交叉保护作用可由DNA质粒载体介导。这一发现应有助于新一代抗细菌疫苗的设计和开发,尤其是针对问号钩端螺旋体复合群。